NCT01556841.

Trial name or title	A phase II study to assess the activity of TroVax® (MVA‐5T4) versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer
Methods	Randomised phase II
Participants	97 participants with CA‐125‐relapsed asymptomatic ovarian cancer
Interventions	Vaccine targeting 5T4 (TroVax) vs placebo
Outcomes	Clinical response Immune response Survival
Starting date	November 2013
Contact information
Notes	Active, not recruiting, December 2017